THE Therapeutic Goods Administration (TGA) has issued an alert to prescribers and dispensers of antifungal miconazole that there is a well-documented potential for drug-drug interaction between the topical drug and warfarin.
Miconazole inhibits one of the main cytochrome P450 isoenzymes involved in warfarin metabolism (CYP2C9), which can result in reduced warfarin clearance and an enhanced anticoagulant effect.
Products the TGA implicated included Daktarin Oral Gel, Decozol Oral Gel and Resolve Thrush Cream.
Warnings on the PI and CMI documents will be enhanced.
See tga.gov.au for more.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Mar 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Mar 18